355 related articles for article (PubMed ID: 32241267)
21. Modulation of semaphorin 3C & 4D expression in cancerous tissues from individuals with laryngeal squamous cell carcinoma.
Sajadian M; Khademi B; Moinzadeh L; Ghaderi A; Jafarzadeh A; Razmkhah M
Indian J Med Res; 2023 Oct; 158(4):432-438. PubMed ID: 38006346
[TBL] [Abstract][Full Text] [Related]
22. Class 3 semaphorins in cardiovascular development.
Valdembri D; Regano D; Maione F; Giraudo E; Serini G
Cell Adh Migr; 2016 Nov; 10(6):641-651. PubMed ID: 27439112
[TBL] [Abstract][Full Text] [Related]
23. Expression of semaphorin class 3 is higher in the proliferative phase on the human endometrium.
Ferreira GD; Capp E; Jauckus J; Strowitzki T; Germeyer A
Arch Gynecol Obstet; 2018 May; 297(5):1175-1179. PubMed ID: 29450692
[TBL] [Abstract][Full Text] [Related]
24. SOX4 transcriptionally regulates multiple SEMA3/plexin family members and promotes tumor growth in pancreatic cancer.
Huang HY; Cheng YY; Liao WC; Tien YW; Yang CH; Hsu SM; Huang PH
PLoS One; 2012; 7(12):e48637. PubMed ID: 23251334
[TBL] [Abstract][Full Text] [Related]
25. Frequent deletion of 3p21.1 region carrying semaphorin 3G and aberrant expression of the genes participating in semaphorin signaling in the epithelioid type of malignant mesothelioma cells.
Yoshikawa Y; Sato A; Tsujimura T; Morinaga T; Fukuoka K; Yamada S; Murakami A; Kondo N; Matsumoto S; Okumura Y; Tanaka F; Hasegawa S; Hashimoto-Tamaoki T; Nakano T
Int J Oncol; 2011 Dec; 39(6):1365-74. PubMed ID: 21842119
[TBL] [Abstract][Full Text] [Related]
26. The role of the semaphorins in cancer.
Neufeld G; Mumblat Y; Smolkin T; Toledano S; Nir-Zvi I; Ziv K; Kessler O
Cell Adh Migr; 2016 Nov; 10(6):652-674. PubMed ID: 27533782
[TBL] [Abstract][Full Text] [Related]
27. Genomic stratification based on microenvironment immune types and PD-L1 for tailoring therapeutic strategies in bladder cancer.
Lyu X; Wang P; Qiao Q; Jiang Y
BMC Cancer; 2021 May; 21(1):646. PubMed ID: 34059019
[TBL] [Abstract][Full Text] [Related]
28. Emerging roles and mechanisms of semaphorins activity in cancer.
Bica C; Tirpe A; Nutu A; Ciocan C; Chira S; Gurzau ES; Braicu C; Berindan-Neagoe I
Life Sci; 2023 Apr; 318():121499. PubMed ID: 36775114
[TBL] [Abstract][Full Text] [Related]
29. Semaphorin Signaling in Cancer-Associated Inflammation.
Franzolin G; Tamagnone L
Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30658382
[TBL] [Abstract][Full Text] [Related]
30. Tumour growth inhibition and anti-metastatic activity of a mutated furin-resistant Semaphorin 3E isoform.
Casazza A; Kigel B; Maione F; Capparuccia L; Kessler O; Giraudo E; Mazzone M; Neufeld G; Tamagnone L
EMBO Mol Med; 2012 Mar; 4(3):234-50. PubMed ID: 22247010
[TBL] [Abstract][Full Text] [Related]
31. Full-Length Semaphorin-3C Is an Inhibitor of Tumor Lymphangiogenesis and Metastasis.
Mumblat Y; Kessler O; Ilan N; Neufeld G
Cancer Res; 2015 Jun; 75(11):2177-86. PubMed ID: 25808871
[TBL] [Abstract][Full Text] [Related]
32. Semaphorins and their receptors in lamprey CNS: Cloning, phylogenetic analysis, and developmental changes during metamorphosis.
Shifman MI; Selzer ME
J Comp Neurol; 2006 Jul; 497(1):115-32. PubMed ID: 16680764
[TBL] [Abstract][Full Text] [Related]
33. Investigation of lipid metabolism dysregulation and the effects on immune microenvironments in pan-cancer using multiple omics data.
Hao Y; Li D; Xu Y; Ouyang J; Wang Y; Zhang Y; Li B; Xie L; Qin G
BMC Bioinformatics; 2019 May; 20(Suppl 7):195. PubMed ID: 31074374
[TBL] [Abstract][Full Text] [Related]
34. The potential of class 3 semaphorins as both targets and therapeutics in cancer.
Mishra R; Kumar D; Tomar D; Chakraborty G; Kumar S; Kundu GC
Expert Opin Ther Targets; 2015 Mar; 19(3):427-42. PubMed ID: 25434284
[TBL] [Abstract][Full Text] [Related]
35. Plexin-a4 mediates axon-repulsive activities of both secreted and transmembrane semaphorins and plays roles in nerve fiber guidance.
Suto F; Ito K; Uemura M; Shimizu M; Shinkawa Y; Sanbo M; Shinoda T; Tsuboi M; Takashima S; Yagi T; Fujisawa H
J Neurosci; 2005 Apr; 25(14):3628-37. PubMed ID: 15814794
[TBL] [Abstract][Full Text] [Related]
36. High-grade serous tubo-ovarian cancer refined with single-cell RNA sequencing: specific cell subtypes influence survival and determine molecular subtype classification.
Olbrecht S; Busschaert P; Qian J; Vanderstichele A; Loverix L; Van Gorp T; Van Nieuwenhuysen E; Han S; Van den Broeck A; Coosemans A; Van Rompuy AS; Lambrechts D; Vergote I
Genome Med; 2021 Jul; 13(1):111. PubMed ID: 34238352
[TBL] [Abstract][Full Text] [Related]
37. Semaphorin signaling in cancer cells and in cells of the tumor microenvironment--two sides of a coin.
Capparuccia L; Tamagnone L
J Cell Sci; 2009 Jun; 122(Pt 11):1723-36. PubMed ID: 19461072
[TBL] [Abstract][Full Text] [Related]
38. A Pan-Cancer Study of Epidermal Growth Factor-Like Domains 6/7/8 as Therapeutic Targets in Cancer.
Shi S; Ma T; Xi Y
Front Genet; 2020; 11():598743. PubMed ID: 33391349
[TBL] [Abstract][Full Text] [Related]
39. Class 3 semaphorins modulate the invasive capacity of rheumatoid arthritis fibroblast-like synoviocytes.
Tang MW; Malvar Fernández B; Newsom SP; van Buul JD; Radstake TRDJ; Baeten DL; Tak PP; Reedquist KA; García S
Rheumatology (Oxford); 2018 May; 57(5):909-920. PubMed ID: 29471421
[TBL] [Abstract][Full Text] [Related]
40. Plate-Based Assay for Measuring Direct Semaphorin-Neuropilin Interactions.
Parker MW; Vander Kooi CW
Methods Mol Biol; 2017; 1493():73-87. PubMed ID: 27787843
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
